Total Payments
$14,579
2024 Payments
$309.69
Companies
14
Transactions
27
Medicare Patients
790
Medicare Billing
$165,651
Payment Breakdown by Category
Consulting$7,056 (48.4%)
Other$4,441 (30.5%)
Research$2,414 (16.6%)
Food & Beverage$606.18 (4.2%)
Education$61.29 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,056 | 3 | 48.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,095 | 5 | 21.2% |
| Unspecified | $2,414 | 5 | 16.6% |
| Honoraria | $1,028 | 1 | 7.0% |
| Food and Beverage | $606.18 | 9 | 4.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $317.75 | 2 | 2.2% |
| Education | $61.29 | 2 | 0.4% |
Payments by Type
General
$12,164
22 transactions
Research
$2,414
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $3,421 | 2 | $0 (2023) |
| Genentech USA, Inc. | $3,364 | 3 | $0 (2019) |
| Astellas Pharma Global Development | $2,414 | 5 | $0 (2019) |
| Amgen Inc. | $2,400 | 1 | $0 (2019) |
| Rigel Pharmaceuticals, Inc. | $1,028 | 1 | $0 (2023) |
| ABBVIE INC. | $616.14 | 4 | $0 (2024) |
| F. Hoffmann-La Roche AG | $585.58 | 3 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $274.39 | 1 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $143.43 | 1 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $109.76 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $309.69 | 5 | JAZZ PHARMACEUTICALS INC. ($143.43) |
| 2023 | $1,426 | 4 | Rigel Pharmaceuticals, Inc. ($1,028) |
| 2022 | $47.00 | 1 | PFIZER INC. ($47.00) |
| 2021 | $3,450 | 2 | Astellas Pharma US Inc ($3,406) |
| 2020 | $550.00 | 1 | AbbVie Inc. ($550.00) |
| 2019 | $8,569 | 10 | Genentech USA, Inc. ($3,361) |
| 2018 | $227.59 | 4 | F. Hoffmann-La Roche AG ($192.43) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $143.43 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/04/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | SOBI, INC | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $100.12 | General |
| Category: HEMATOLOGY | ||||||
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $274.39 | General |
| 10/02/2023 | TAIHO ONCOLOGY, INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $109.76 | General |
| 04/26/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,027.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/03/2023 | Astellas Pharma US Inc | Xospata (Drug) | Education | In-kind items and services | $14.29 | General |
| Category: Oncology | ||||||
| 10/27/2022 | PFIZER INC. | BOSULIF (Drug) | Education | In-kind items and services | $47.00 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $43.36 | General |
| Category: ONCOLOGY | ||||||
| 01/13/2021 | Astellas Pharma US Inc | XOSPATA (Drug) | Consulting Fee | Cash or cash equivalent | $3,406.25 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2020 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: ONCOLOGY | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | VENCLEXTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $228.15 | General |
| Category: BioOncology | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | VENCLEXTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $165.00 | General |
| Category: BioOncology | ||||||
| 12/06/2019 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 10/22/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $290.32 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 03/25/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $533.33 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 03/25/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $517.24 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 02/13/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $883.33 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 02/08/2019 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $261.33 | General |
| Category: BioOncology | ||||||
| 02/07/2019 | Genentech USA, Inc. | VENCLEXTA (Biological) | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| Category: BioOncology | ||||||
| 01/09/2019 | Astellas Pharma Global Development | XOSPATA (Drug) | — | In-kind items and services | $190.26 | Research |
| Study: A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation • Category: ONCOLOGY | ||||||
| 12/31/2018 | F. Hoffmann-La Roche AG | VENCLEXTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $192.43 | General |
| Category: BioOncology | ||||||
| 10/24/2018 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $12.45 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $2,414 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 207 | 365 | $278,893 | $35,102 |
| 2022 | 6 | 228 | 467 | $346,279 | $45,810 |
| 2021 | 6 | 217 | 523 | $364,655 | $54,374 |
| 2020 | 4 | 138 | 331 | $240,279 | $30,365 |
Total Patients
790
Total Services
1,686
Medicare Billing
$165,651
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 64 | 157 | $121,361 | $18,395 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 60 | 91 | $52,507 | $6,658 | 12.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 32 | $17,632 | $3,432 | 19.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $22,785 | $3,406 | 15.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 37 | 41 | $60,928 | $2,641 | 4.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 14 | 23 | $3,680 | $569.72 | 15.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 71 | 203 | $156,919 | $24,480 | 15.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 104 | $57,304 | $9,468 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 63 | $36,351 | $4,544 | 12.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 46 | 49 | $68,600 | $3,343 | 4.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $22,785 | $3,259 | 14.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 17 | 27 | $4,320 | $716.05 | 16.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 77 | 244 | $188,612 | $29,746 | 15.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 137 | $74,774 | $12,651 | 16.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 87 | $50,199 | $6,739 | 13.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $23,870 | $3,497 | 14.6% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 18 | 19 | $24,960 | $1,336 | 5.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 11 | 14 | $2,240 | $405.86 | 18.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 209 | $161,557 | $19,310 | 12.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 52 | $27,664 | $4,847 | 17.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 28 | 49 | $28,273 | $3,258 | 11.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $22,785 | $2,950 | 12.9% |
About Dr. Rebecca Olin, MD
Dr. Rebecca Olin, MD is a Hematology & Oncology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043373681.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rebecca Olin, MD has received a total of $14,579 in payments from pharmaceutical and medical device companies, with $309.69 received in 2024. These payments were reported across 27 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($7,056).
As a Medicare-enrolled provider, Olin has provided services to 790 Medicare beneficiaries, totaling 1,686 services with total Medicare billing of $165,651. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location San Francisco, CA
- Active Since 12/18/2006
- Last Updated 11/17/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043373681
Products in Payments
- XOSPATA (Drug) $5,821
- VENCLEXTA (Biological) $3,950
- Blincyto (Biological) $2,400
- Rezlidhia (Drug) $1,028
- VENCLEXTA (Drug) $570.88
- RYLAZE (Drug) $143.43
- GAMIFANT (Drug) $100.12
- BOSULIF (Drug) $47.00
- IMBRUVICA (Drug) $45.26
- TIBSOVO (Drug) $43.36
- Yescarta (Drug) $32.42
- Xospata (Drug) $14.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Francisco
Dr. Terence Friedlander, Ms, MS
Hematology & Oncology — Payments: $248,592
Hematology & Oncology $248,592
Pamela Munster, Md, MD
Hematology & Oncology — Payments: $98,260
Hematology & Oncology $98,260
Dr. Caroline Behler, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $64,653
Hematology & Oncology $64,653
David Oh
Hematology & Oncology — Payments: $57,997
Hematology & Oncology $57,997
Dr. Paul Volberding, Md, MD
Hematology & Oncology — Payments: $51,997
Hematology & Oncology $51,997
Dr. Alain Algazi, M.d, M.D
Hematology & Oncology — Payments: $24,175
Hematology & Oncology $24,175